P2RY12 and chronic kidney disease: The endpoint of major bleeding occurred in 64 (4.56%) and 221 (2.50%) patients with P2Y12 inhibitor monotherapy, and 94 (6.54%) and 332 (3.77%) patients with DAPT in CKD and non-CKD patients, respectively.